Overview: Anti-Mitochondrial Antibody (AMA-M2) IgG Rapid TestIntroduction: The Anti-Mitochondrial Antibody (AMA-M2) IgG Rapid Test is a diagnostic tool designed to detect AMA-M2 IgG antibodies in serum, whole blood, or saliva samples, facilitating the screening of primary biliary cholangitis (PBC). These autoantibodies are highly specific for PBC, presenting with fatigue, jaundice, and severe complications like cirrhosis or liver failure if untreated, particularly in middle-aged women. Per the 2023 American Association for the Study of Liver Diseases guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a valuable tool for initial screening in hepatology clinics. This rapid diagnostic falls under immunology and targets individuals with liver symptoms or autoimmune history, addressing the challenge of early detection to guide ursodeoxycholic acid therapy. With morbidity rates elevated due to progressive liver damage, the test supports public health efforts by enabling early identification, facilitating specialist referrals, and reducing liver-related mortality. Its multi-sample capability enhances its utility.Other Names: AMA-M2 IgG Rapid Test.FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Inova Diagnostics, this test advanced PBC detection, providing a rapid alternative to ELISA.Purpose: The test screens for AMA-M2 IgG to guide primary biliary cholangitis diagnosis, assess disease activity, and inform treatment and prevention strategies.Test Parameters: Presence of AMA-M2 IgG Antibody, detected with high specificity to indicate autoimmune activity, typically detectable in serum or blood during active PBC.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fatigue, jaundice, or pruritus.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fatigue, jaundice, pruritus, or prior liver conditions, as well as any family history of autoimmune diseases or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated PBC including cirrhosis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent liver injury can affect results. Correlation with liver biopsy or imaging is recommended to confirm findings.Clinical Significance: A positive result indicates possible PBC, necessitating further investigation like liver biopsy or ursodeoxycholic acid therapy. A negative result may require follow-up testing if symptoms persist, especially if sampled during inactive disease.Specialist Consultation: Hepatologists should be consulted for case management, treatment planning, and coordination with liver disease programs.Additional Supporting Tests: Liver biopsy, imaging, or AMA-M2 follow-up assays for confirmation.Test Limitations: The test may produce false negatives in early disease or false positives in other liver conditions, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AASLD Guidelines 2023, Hepatology 2024, Journal of Immunology 2025.